By Connor Hart
Five Below issued an upbeat outlook for its current fiscal year ahead as it posted a narrower-than-expected decline in comparable sales during its fiscal fourth quarter. The low-cost retailer's mid-2024 reset resulted in a better-than-expected end to the year, and momentum is expected to continue into its fiscal 2025. Same-store sales fell 3.0% in its recent quarter, better than the 3.3% decline expected by Wall Street. Shares rise 9.6%, to $82.88, in after-hours trading.
ProAssurance inked a roughly $1.3 billion deal to be bought by The Doctors Co. Under the agreement, ProAssurance's stockholders would receive $25 a share in cash, representing a roughly 60% premium to Wednesday's closing price. The deal is expected to close in the first half of 2026, pending approval by the specialty insurer's shareholders. Shares surge 51%, to $23.40, in post-market trading.
Akebia Therapeutics commenced an underwritten public offering. The biopharmaceutical company didn't say how many shares of its common stock it expects to sell, nor did it disclose anticipated proceeds. It said all shares are being offered by the company. Shares fall 21%, to $2.25, in after-hours trading.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
March 19, 2025 19:11 ET (23:11 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。